Trial Profile
A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Napabucasin (Primary) ; Bevacizumab; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin; Regorafenib
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boston Biomedical; Sumitomo Pharma Oncology
- 17 Jul 2020 Status changed from active, no longer recruiting to completed.
- 17 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.
- 06 Oct 2017 Status changed from recruiting to active, no longer recruiting.